Focal regression of a primary melanoma, fading lentigines, and poliosis in metastatic melanoma treated with anti-PD-1

Pembrolizumab(®) , a first line immune checkpoint inhibitor, has shown good clinical activity with an acceptable safety profile, in the management of metastatic melanoma.(1, 2) We report a patient with metastatic melanoma, treated with anti-PD-1, who demonstrated metastatic disease regression, focal complete regression of a primary melanoma, partial regression of several solar lentigines, and a patch of poliosis superficial to a thigh metastatic deposit. This article is protected by copyright. All rights reserved.